MedTrace Logo

Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation

NCT04711226 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-08-10

No results posted yet for this study

Summary

This study will evaluate the safety, tolerability and efficacy of AT-1501 in an immunomodulation regimen in adult patients with T1D undergoing an islet cell transplant.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

DRUG

AT-1501

AT-1501 IV infusion

Sponsors & Collaborators

  • Anelixis Therapeutics, LLC

    lead INDUSTRY

Principal Investigators

  • Jeff Bornstein, MD · Eledon Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-19
Primary Completion
2024-06-30
Completion
2026-06-30
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04711226 on ClinicalTrials.gov